Paul L Reiter1, Mira L Katz, Electra D Paskett. 1. Division of Cancer Prevention and Control, College of Medicine, The Ohio State University, Suite 525, 1590 North High Street, Columbus, Ohio 43201, USA. Paul.Reiter@osumc.edu
Abstract
BACKGROUND: Appalachia is a geographic region with high cervical cancer incidence and mortality rates, yet little is known about human papillomavirus (HPV) vaccination in this region. We determined HPV vaccine coverage among adolescent females from Appalachia, made comparisons to non-Appalachian females, and examined how coverage differs across subregions within Appalachia. METHODS: We analyzed data from the National Immunization Survey-Teen 2008-2010 for adolescent females ages 13-17 (n = 1,951, Appalachian females and n = 25,468, non-Appalachian females). We examined HPV vaccine initiation (receipt of at least one dose), completion (receipt of at least three doses), and follow-through (completion among initiators). Analyses used weighted logistic regression. RESULTS: HPV vaccine initiation [Appalachian = 40.8% vs. non-Appalachian = 43.6%; OR, 0.92; 95% confidence interval (CI), 0.79-1.07] and completion (Appalachian = 27.7% vs. non-Appalachian = 25.3%; OR, 1.12; 95% CI, 0.95-1.32) were similar between Appalachian and non-Appalachian females. HPV vaccine follow-through was higher among Appalachian females than non-Appalachian females (67.8% vs. 58.1%; OR, 1.36; 95% CI, 1.07-1.72). Vaccination outcomes tended to be higher in the Northern (completion and follow-through) and South Central (follow-through) subregions of Appalachia compared with non-Appalachian United States. Conversely, vaccination outcomes tended to be lower in the Central (initiation and completion) and Southern (initiation and completion) subregions. CONCLUSIONS: In general, HPV vaccination in Appalachia is mostly similar to the rest of the United States. However, vaccination is lagging in regions of Appalachia where cervical cancer incidence and mortality rates are highest. IMPACT: Current cervical cancer disparities could potentially worsen if HPV vaccine coverage is not improved in regions of Appalachia with low HPV vaccine coverage.
BACKGROUND: Appalachia is a geographic region with high cervical cancer incidence and mortality rates, yet little is known about human papillomavirus (HPV) vaccination in this region. We determined HPV vaccine coverage among adolescent females from Appalachia, made comparisons to non-Appalachian females, and examined how coverage differs across subregions within Appalachia. METHODS: We analyzed data from the National Immunization Survey-Teen 2008-2010 for adolescent females ages 13-17 (n = 1,951, Appalachian females and n = 25,468, non-Appalachian females). We examined HPV vaccine initiation (receipt of at least one dose), completion (receipt of at least three doses), and follow-through (completion among initiators). Analyses used weighted logistic regression. RESULTS:HPV vaccine initiation [Appalachian = 40.8% vs. non-Appalachian = 43.6%; OR, 0.92; 95% confidence interval (CI), 0.79-1.07] and completion (Appalachian = 27.7% vs. non-Appalachian = 25.3%; OR, 1.12; 95% CI, 0.95-1.32) were similar between Appalachian and non-Appalachian females. HPV vaccine follow-through was higher among Appalachian females than non-Appalachian females (67.8% vs. 58.1%; OR, 1.36; 95% CI, 1.07-1.72). Vaccination outcomes tended to be higher in the Northern (completion and follow-through) and South Central (follow-through) subregions of Appalachia compared with non-Appalachian United States. Conversely, vaccination outcomes tended to be lower in the Central (initiation and completion) and Southern (initiation and completion) subregions. CONCLUSIONS: In general, HPV vaccination in Appalachia is mostly similar to the rest of the United States. However, vaccination is lagging in regions of Appalachia where cervical cancer incidence and mortality rates are highest. IMPACT: Current cervical cancer disparities could potentially worsen if HPV vaccine coverage is not improved in regions of Appalachia with low HPV vaccine coverage.
Authors: Eugene J Lengerich; Thomas C Tucker; Raymond K Powell; Pat Colsher; Erik Lehman; Ann J Ward; Jennifer C Siedlecki; Stephen W Wyatt Journal: J Rural Health Date: 2005 Impact factor: 4.333
Authors: Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford Journal: Int J Cancer Date: 2007-08-01 Impact factor: 7.396
Authors: A B Moscicki; S Shiboski; J Broering; K Powell; L Clayton; N Jay; T M Darragh; R Brescia; S Kanowitz; S B Miller; J Stone; E Hanson; J Palefsky Journal: J Pediatr Date: 1998-02 Impact factor: 4.406
Authors: Robin C Vanderpool; Emily Van Meter Dressler; Lindsay R Stradtman; Richard A Crosby Journal: J Rural Health Date: 2015-01-14 Impact factor: 4.333
Authors: Electra Paskett; Beti Thompson; Alice S Ammerman; Alexander N Ortega; Jill Marsteller; DeJuran Richardson Journal: Health Aff (Millwood) Date: 2016-08-01 Impact factor: 6.301
Authors: Paul L Reiter; Noel T Brewer; Melissa B Gilkey; Mira L Katz; Electra D Paskett; Jennifer S Smith Journal: Cancer Date: 2014-06-19 Impact factor: 6.860
Authors: Parth D Shah; Justin G Trogdon; Shelley D Golden; Carol E Golin; Macary Weck Marciniak; Noel T Brewer Journal: Milbank Q Date: 2018-09 Impact factor: 4.911